Switch theme
Sign up to access all valuation multiples
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).
2015
13
LTM Revenue n/a
LTM EBITDA -$8.7M
$3.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TME Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of -$8.7M.
In the most recent fiscal year, TME Pharma achieved revenue of n/a and an EBITDA of -$5.4M.
TME Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TME Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$5.4M | -$5.2M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$15.5M | -$16.3M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, TME Pharma's stock price is EUR 0 (or $0).
TME Pharma has current market cap of EUR 6.3M (or $6.8M), and EV of EUR 3.6M (or $3.9M).
See TME Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.9M | $6.8M | XXX | XXX | XXX | XXX | $-0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, TME Pharma has market cap of $6.8M and EV of $3.9M.
TME Pharma's trades at n/a LTM EV/Revenue multiple, and -0.4x LTM EBITDA.
Analysts estimate TME Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for TME Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | XXX | XXX |
| P/E | -1.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTME Pharma's NTM/LTM revenue growth is n/a
TME Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.
Over next 12 months, TME Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate TME Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for TME Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TME Pharma acquired XXX companies to date.
Last acquisition by TME Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . TME Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was TME Pharma founded? | TME Pharma was founded in 2015. |
| Where is TME Pharma headquartered? | TME Pharma is headquartered in France. |
| How many employees does TME Pharma have? | As of today, TME Pharma has 13 employees. |
| Is TME Pharma publicy listed? | Yes, TME Pharma is a public company listed on PAR. |
| What is the stock symbol of TME Pharma? | TME Pharma trades under ALTME ticker. |
| When did TME Pharma go public? | TME Pharma went public in 2016. |
| Who are competitors of TME Pharma? | Similar companies to TME Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of TME Pharma? | TME Pharma's current market cap is $6.8M |
| What is the current EBITDA of TME Pharma? | TME Pharma's last 12-month EBITDA is -$8.7M. |
| What is the current EV/EBITDA multiple of TME Pharma? | Current EBITDA multiple of TME Pharma is -0.4x. |
| Is TME Pharma profitable? | Yes, TME Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
